Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support potential best-in-class profile On track to report Phase 2...

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results Continued advancement of pipeline and execution towards expected milestones, including APG777 16-week proof-of-concept data from the Phase 2 Part A trial in 2H 2025, APG808 interim Phase 1 data in 4Q...